Finance
Bristol Myers Squibb's approval of Zenbexus for multiple myeloma highlights its new drug class, while a lawsuit over delayed approvals remains unresolved.
Technology
Valisure is suing U.S. Pharmacopeia, alleging false claims about its drug testing methods and an attempt to undermine its reputation.
Technology
Bristol Myers Squibb's Zenbexus, a groundbreaking oral therapy for multiple myeloma, has gained FDA approval, marking a significant milestone in treatment options.
Technology
The CMS's recent ruling against funding pediatric gender-affirming treatment could face robust legal challenges, impacting future healthcare practices.
Finance
Today, vehicles monitor driver behavior, feeding data to insurers who adjust premiums based on the findings.
Finance
Community connections are vital for health yet overlooked in the U.S. and U.K. healthcare funding and discussions.
Technology
Commure has suspended payments under its referral program tied to AI products, just days before a critical investigation was published.
Technology
Splitting the MMR vaccine could lead to missed doses and increased illness among children, echoing past lessons from vaccine history.
Technology
FDA nixes a radiopharma drug by ITM Isotope Technologies, while Hims & Hers plans to enter the peptides market amidst evolving regulations.
Technology
Skylark Bio has initiated a clinical trial aimed at treating hearing loss in children with GJB2 mutations, following advancements in gene therapy.
Technology
Abortion care is evolving, with patients increasingly turning to digital solutions for reliable information and medical guidance.
Technology
MoonLake Immunotherapeutics faces scrutiny for vague disclosures on its autoimmune drug candidate, raising questions about its trial results’ credibility.
Technology
Nurses are increasingly spotlighting the risks of clinical AI, advocating for a collaborative approach to its development and deployment in healthcare.
Technology
Medicare's “Bridge” program aims to lower costs for GLP-1 medications, yet its complexity may hinder patient access to affordable treatments.
Technology
The FDA has rejected ITM-11 due to manufacturing concerns, hindering its potential as a competitor to Novartis’ treatment for rare neuroendocrine tumors.